London, UK – [Insert Date] – Scancell Holdings plc, a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer, has announced a significant stride forward in its mission to combat advanced melanoma. The company has secured Clinical Trial Authorisation (CTA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a large-scale Phase III clinical trial for its lead product candidate, iSCIB1+. This pivotal study, designed as a placebo-controlled, registrational, double-blind, and randomized trial, will evaluate the efficacy and safety of iSCIB1+ in combination with ipilimumab and nivolumab, two established checkpoint inhibitors, for patients with stage III or IV unresectable melanoma.
The commencement of this Phase III trial represents a critical juncture for Scancell, building upon promising earlier clinical data and positioning iSCIB1+ as a potential next-generation immunotherapy for a disease with significant unmet medical needs. The global scope of the trial, encompassing approximately 90 sites across Australia, Canada, the European Union, the United Kingdom, and the United States, underscores the company’s commitment to rapidly generating robust data that could support regulatory submissions worldwide.
Main Facts: A Global Endeavor to Combat Advanced Melanoma
The forthcoming Phase III trial is set to enroll 550 participants diagnosed with stage III or IV unresectable melanoma, a diagnosis that signifies a serious and often life-threatening stage of the disease. Patients will be meticulously randomized in a 1:1 ratio, a design intended to ensure unbiased comparison between the treatment arms. One arm will receive 8mg of iSCIB1+ administered in conjunction with ipilimumab and nivolumab. The control arm will receive a placebo, also administered alongside ipilimumab and nivolumab. This rigorous design aims to isolate the specific contribution of iSCIB1+ to the overall therapeutic effect.
The primary objective of this registrational trial is to evaluate progression-free survival (PFS) as the main endpoint. PFS measures the length of time during and after treatment that a patient lives with the disease without the cancer worsening. This endpoint is particularly crucial for accelerated approval pathways, allowing for earlier access to potentially life-saving treatments. Overall survival (OS), a measure of the length of time patients live after starting treatment, is designated as a key secondary endpoint. Positive OS data would be instrumental in supporting a full approval application at a later stage.
The strategic placement of approximately 90 clinical trial sites across a geographically diverse range of countries – Australia, Canada, the EU, the UK, and the US – is a testament to Scancell’s ambition to accelerate recruitment and ensure the broadest possible access for eligible patients. This global approach not only facilitates faster enrollment but also enhances the generalizability of the trial results across diverse patient populations.
Chronology: A Phased Approach Towards Regulatory Approval
The journey leading to this pivotal Phase III trial has been characterized by careful planning and incremental progress, grounded in scientific rigor. The initial clearance for this study follows the successful submission and approval of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) in January 2026. This significant regulatory hurdle in the United States paved the way for the broader international trial initiation.
Scancell anticipates that the Phase III trial will commence by the end of 2026. The company has set an ambitious target for reporting initial PFS data in the second half of 2028, a timeline that reflects the urgency of bringing a new treatment option to patients. This projected timeline highlights the company’s proactive approach to clinical development and its commitment to efficient trial execution.
The design of the current Phase III trial has been significantly informed by the compelling data generated from the earlier Phase II SCOPE trial. In this prior study, the combination of iSCIB1+ with ipilimumab and nivolumab demonstrated a remarkable sustained PFS rate of 77% after 22 months. Furthermore, the trial reported an impressive OS rate of 87.4% at 18 months within the targeted patient population. These robust results from the Phase II study provided the critical scientific rationale and confidence to advance iSCIB1+ into a larger, registrational Phase III trial.
Supporting Data: The Science Behind iSCIB1+
iSCIB1+ is not a conventional therapeutic agent; it represents a novel approach to cancer immunotherapy. It is classified as a deoxyribonucleic acid (DNA) ImmunoBody, a platform technology developed by Scancell. This innovative therapy is administered via a needle-free intramuscular injection, a method designed to enhance patient comfort and compliance.
The mechanism of action of iSCIB1+ is intricately linked to its ability to stimulate a potent anti-tumor immune response. The DNA encoding within iSCIB1+ directs the body to produce an antibody that specifically targets melanoma-associated antigens, namely gp100 and tyrosinase-related protein 2 (TRP-2). These antigens are frequently expressed on the surface of melanoma cells, making them ideal targets for the immune system. By presenting these antigens to the immune system, iSCIB1+ effectively primes and activates T cells, the body’s primary cellular defense against cancer. This targeted T cell activation is designed to elicit a robust and sustained immune response that can recognize and destroy melanoma cells, even those that are resistant to conventional therapies.
The Phase II SCOPE trial provided crucial proof-of-concept for this mechanism. The sustained high PFS and OS rates observed in that study suggest that iSCIB1+ can effectively augment the anti-tumor activity of existing checkpoint inhibitors, potentially overcoming resistance mechanisms and leading to more durable responses in patients with advanced melanoma. The ability of iSCIB1+ to stimulate a broad T cell response against multiple tumor-associated antigens is a key differentiator, offering the potential to overcome tumor heterogeneity and reduce the likelihood of immune escape.
Official Responses: A Milestone for Scancell and Patients
The MHRA’s CTA for the Phase III trial marks a significant regulatory milestone for Scancell Holdings. Dr. Phil L’Huillier, CEO of Scancell, expressed his enthusiasm and optimism regarding this development. "Our regulatory strategy continues to build momentum," Dr. L’Huillier stated. "The MHRA CTA for the Phase III trial of our lead asset iSCIB1+ in patients with advanced melanoma is an important milestone, bringing us one step closer to delivering iSCIB1+ to patients in a global registrational trial setting."
Dr. L’Huillier further emphasized the significance of this step: "This authorization from the MHRA, alongside prior clearance from the US FDA, validates the scientific merit and potential of iSCIB1+ and underscores our commitment to advancing this promising therapy through rigorous clinical evaluation. We are eager to initiate this global trial and work collaboratively with our investigators and patients to generate the data needed to potentially bring this innovative treatment to those who need it most."
It is important to note, as highlighted by Scancell, that iSCIB1+ remains an investigational product. It has not yet received regulatory approval for melanoma or any other indication from regulatory bodies such as the MHRA or FDA. The safety and efficacy of iSCIB1+ are still under evaluation in ongoing clinical trials.
Implications: A Potential Paradigm Shift in Melanoma Treatment
The progression of iSCIB1+ into a global Phase III registrational trial holds significant implications for the future of advanced melanoma treatment. Melanoma, particularly in its advanced stages, remains a challenging disease to treat, and while significant advancements have been made with the advent of immunotherapy, a substantial proportion of patients still experience disease progression or relapse.
The data emerging from the Phase II SCOPE trial, showing high PFS and OS rates, suggest that iSCIB1+ could offer a synergistic benefit when combined with existing checkpoint inhibitors. This could translate into improved outcomes for a wider spectrum of patients, potentially including those who do not respond adequately to current standard-of-care therapies or those who develop resistance over time.
If the Phase III trial demonstrates statistically significant and clinically meaningful improvements in PFS and OS, it could pave the way for regulatory approval of iSCIB1+ as a new therapeutic option for advanced melanoma. This would not only represent a major commercial success for Scancell Holdings but, more importantly, would provide a much-needed new weapon in the oncologist’s arsenal against this devastating disease.
The development of iSCIB1+ also speaks to the broader advancements in the field of cancer immunotherapy. The focus on stimulating robust T cell responses against tumor-associated antigens, coupled with the innovative DNA ImmunoBody platform, highlights the ongoing quest for more effective and durable cancer treatments. The success of iSCIB1+ could inspire further research and development in similar therapeutic modalities, potentially leading to breakthroughs in the treatment of other difficult-to-treat cancers.
The global nature of the Phase III trial also signifies a maturing landscape for clinical research, with a greater emphasis on international collaboration to accelerate the development and accessibility of novel therapies. As the trial progresses, the global medical and patient communities will be keenly watching for the data that could redefine the treatment paradigm for advanced melanoma.
About the Author
